echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Revealed: India, the Philippines, Afghanistan and other competition to introduce, China's new crown vaccine in the end where strong?

    Revealed: India, the Philippines, Afghanistan and other competition to introduce, China's new crown vaccine in the end where strong?

    • Last Update: 2020-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In November, the world is likely to officially welcome its first new crown vaccine.
    is now less than 10 months away from the first known case of new coronary pneumonia.
    is much faster than the 8-10 years it takes for a typical vaccine to be developed.
    is our country in this vaccine race? What method was used? How do you win global recognition? China's new crown vaccine development progress leading the world according to the new drug research and development monitoring database (CPM) shows that the world has 195 products about the new crown vaccine, of which 8 into the clinical Phase III trial, and China's independent research and development accounted for 4.
    new drug research and development monitoring database (CPM), China's vaccine companies have also signed cooperation agreements with institutions in several countries to jointly implement Phase III clinical trials on the basis of compliance with the law.
    phase III clinical trials in the Middle East of China's two inactivated vaccines have been conducted and more than 35,000 people have been vaccinated.
    inactivated vaccine in South America and Southeast Asia, the phase III clinical trial was carried out, and the vaccination work was carried out in an orderly manner.
    adenovirus vector vaccine jointly developed by the Chinese Academy of Military Medicine and Consino has been approved for Phase III clinical trials in the countries concerned in the Eurasian region and is currently in the group.
    , the UAE's Ministry of Health and Prevention announced that it had "urgently approved" the launch of a new crown inactivated vaccine for Chinese organisms.
    government also plans to approve the use of the Chinese vaccine by early next year.
    President Duterte also expressed hope that the Philippines will be one of the first countries to use China to develop a new crown vaccine.
    Yang Zhanqiu, a professor of virus at Wuhan University's Department of Medicine, said, "The first approval of China's new crown vaccine by other countries shows that the vaccine developed in China has made a huge leap from laboratory to official approval, which is a world-recognized qualitative change in China's vaccine."
    " new crown vaccine effectiveness and safety vaccine quality is to ensure the basis of preclinical research, clinical research and product launch, the national vaccine market and application, there are strict laws, regulations and technical standards.
    The Vaccine Management Law, which was implemented on December 1, 2019, is the first special law on vaccine management in China and the world, and implements the scientific concepts of safety first, risk management, full control, scientific supervision and social co-management.
    china is currently in accordance with the five technical routes to carry out the emergency development of new crown vaccines, all kinds of vaccines in the preclinical research process, technical characteristics and requirements are different.
    safety and effectiveness of factors affecting safety and effectiveness is an important factor affecting the success of the development of the new crown vaccine, along with the differences in the vaccine preparation process, will lead to different safety problems.
    Such as the biological characteristics of the vaccine itself can induce adverse reactions and accidental infections of the human immune system, the purity and stability of the vaccine can cause local inflammation and allergic reactions, the stability of the preparation process, the addition of adages, and even inactivation in the preparation project incomplete, toxicity reversal and other factors may affect the safety of clinical use.
    August 14, the Drug Review Center of the State Drug Administration issued a circular on the "Technical Guidelines for the Development of Vaccines for The Prevention of New Coronavirus (Trial)" and other five guiding principles, so that the clinical research and development of China's new crown vaccine has a reference to the national technical standards.
    drug review center said that in order to strengthen the clinical evaluation of the new crown vaccine guidance, to promote the new crown vaccine as soon as possible, reference to the WHO issued the target product characteristics formed this guideline.
    in order to ensure that the widely available new crown vaccine can have the desired effect, the Drug Review Center suggested that its protection of the target population should be more than 70 per cent effective, at least 50 per cent.
    addition, vaccines are best protected for one year or more and at least six months.
    vaccine is available, "the safety and clinical protection effects of widespread vaccination should continue to be observed and research continued on the persistence of protection".
    is a sure shot in the arm for the recent debate about the effectiveness and duration of the new crown vaccine.
    after the launch of the new crown vaccine, however, even if the above products go well, the new crown vaccine will face much greater demand than supply in the early stages of the market.
    access to the vaccine will be the focus of public attention.
    at your own expense or free of charge? According to China's current Vaccine Management Law and the National Immunization Program formulated by the State Council, China's human vaccines are divided into the first and second types of vaccines.
    The first type of vaccine refers to the vaccine provided free of charge by the government to citizens, which shall be given in accordance with the provisions of the government, including the vaccine determined by the national immunization plan, the vaccine added by the people's governments of the provinces, autonomous regions and municipalities directly under the Central Government in the implementation of the national immunization plan, and the vaccines used by the people's governments at or above the county level or their health authorities for emergency vaccination or mass vaccination;
    national immunization plan developed by the State Council, including a routine childhood immunization program for school-age children and an emergency immunization plan for adults and key populations for emergency or mass vaccination.
    After the new crown vaccine is listed, the competent department of health under the State Council may consider whether to include the new crown vaccine in the vaccine type of the national immunization plan according to factors such as the epidemic situation of the new crown epidemic and the immunization status of the population nationwide, and report it to the State Council for approval.
    If the new crown vaccine is not included in the national immunization plan, the people's governments of the provinces, autonomous regions and municipalities directly under the Central Government may also decide whether to increase the new crown vaccine to the types of vaccines provided free of charge to citizens in the regional immunization plan and implement free mass vaccination in the region;
    other low-risk areas can reduce the financial burden by introducing population classification and booking out-of-the-fund vaccination models in the light of the current second-class vaccine management system.
    the last kilometer of the new crown vaccine? Since 2016, China's vaccine procurement gradually explore the establishment of the provincial disease control unit responsible for centralized procurement system.
    Whether it is a first-class vaccine or a second-class vaccine, under the current centralized vaccine procurement system, it is necessary to be centrally procured by the government through the provincial public resources trading platform, and then transported through cold chain facilities and equipment to local CDC and vaccination clinics.
    by the government centralized procurement, by enterprises directly to the county-level disease control agencies distribution has greatly reduced the circulation of intermediate links may be problems.
    can predict that if the vaccine is sufficiently available, the average person will only need to contact their local CDC or vaccination clinic to get a new crown vaccine.
    But in the early days of vaccine market, vaccine production capacity is still climbing, and at a time when demand for vaccines is greatest, the efficiency and fairness of vaccine control from the shop floor to vaccination will be another test for the government.
    the final link before the use of the new crown vaccine, we must take into account the rationality and fairness of the policy.
    the eve of the launch of the new crown vaccine, the provinces to coordinate the initial procurement volume, as far as possible in accordance with the needs of the current key population in the provinces, reasonable distribution of vaccine production capacity, while doing a good job of information publicity.
    also reserved part of the vaccine through the appointment system, fair and orderly arrangements for the need for mass vaccination.
    after the vaccine is on the market, clinical research should be continued after the market, and new findings or problems after the vaccine market should be notified in a timely manner.
    new crown outbreak is generally controllable in China, a large number of new crown vaccine production plant in a short period of time will inevitably lead to the waste of follow-up production capacity, the unpredictable progress of the epidemic to reasonable capacity design challenges.
    the background that the new crown epidemic has been effectively controlled in our country, it is not necessary for the low-risk areas to carry out mass vaccination in the short term.
    , the government needs to do a good job of information and education to guide the public to get the new crown vaccine in a reasonable and orderly manner.
    pharmadl Source: Pharmaceutical Geo-Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    reproduce content at the same time does not represent the position of this site.
    leave a message here.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.